Japan implements structural drug pricing reforms impacting global pharmaceutical margins

Japan has shifted its drug pricing methodology to align more closely with international benchmarks, ending its historical isolation from global market trends. This policy change forces multinational pharmaceutical firms to re-evaluate their pricing strategies and revenue projections in the Japanese market, potentially pressuring global profit margins.